eculizumab PNH
Selected indexed studies
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. (Blood, 2019) [PMID:30510080]
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. (Blood, 2019) [PMID:30510079]
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (N Engl J Med, 2021) [PMID:33730455]
_Worker-drafted node — pending editorial review._
Connections
eculizumab PNH is a side effect of
Sources
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. (2023) pubmed
- Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. (2025) pubmed
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (2021) pubmed
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (2006) pubmed
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. (2019) pubmed
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. (2019) pubmed
- How I treat paroxysmal nocturnal hemoglobinuria. (2021) pubmed
- Paroxysmal nocturnal hemoglobinuria. (2014) pubmed
- Paroxysmal nocturnal haemoglobinuria. (2017) pubmed
- Pegcetacoplan versus Eculizumab in PNH. (2021) pubmed